(SLDB) – Globe Newswire
-
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
-
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
-
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
-
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
-
Solid Biosciences Announces $109 Million Private Placement
-
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
-
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
-
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
-
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
-
Solid Biosciences to Participate at Jefferies London Healthcare Conference
-
Solid Biosciences Provides Third Quarter Business Update and Financial Results
-
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
-
Solid Biosciences Provides Second Quarter Business Update and Financial Results
-
Solid Biosciences to Participate at the Jefferies Healthcare Conference
-
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
-
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
-
Solid Biosciences Provides First Quarter Business Update and Financial Results
-
Solid Biosciences to Present at JMP Securities Life Sciences Conference
-
Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
-
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
-
Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
-
Solid Biosciences to Present at Barclays Global Healthcare Conference
-
Solid Biosciences to Present at SVB Securities Global Biopharma Conference
-
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrop
-
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
-
Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases
-
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
-
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
-
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
-
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
-
Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference
-
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
-
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
-
Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
-
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
-
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
-
Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
-
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
-
Solid Biosciences to Participate at the Jefferies Healthcare Conference
Back to SLDB Stock Lookup
